NCT01179412

CompletedPhase 4

Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-...

Mahidol University Source

Compare

Other study identifiers

Sponsor study identifier

EKC2004

Study Type

interventional

Actual enrollment (reported)

172

Locations

1 country

Sites

1

Timeline

Study Start

July 2004

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2009

Actual (reported)

Study Completion

December 2009

Actual (reported)

Brief Summary

The purpose of this study is to determine the outcomes of treating epidemic keratoconjunctivitis with 2% povidone-iodine.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 172 participants
Study completion date: December 2009
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2004
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
December 2009
Actual (reported)
Study Completion
December 2009
Actual (reported)
First Submitted
July 18, 2010
Actual (reported)
First Posted
August 11, 2010
Actual (reported)

Last Updated: August 11, 2010
Status Verified: August 2010
Last Update Submitted: August 10, 2010

Conditions

Viral Conjunctivitis

Outcome Measures

Primary Outcomes (1)

the recovery rate within one week of treatment
1 week

Secondary Outcomes (1)

drug tolerability
1 week

Study Arms (1)

2% povidone-iodine

EXPERIMENTAL

Drug: 2% povidone-iodine

Interventions

2% povidone-iodineDrug

apply 4 times a day for one week

Also known as: PVP-I

2% povidone-iodine

2% povidone-iodineDrug

apply 2% povidone-iodine 4 times per day for one week

Also known as: PVP-I

Eligibility Criteria

Age7 Years+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

patients who were diagnosed with EKC at the outpatient ophthalmic unit

You may not qualify if:

Sponsors & Collaborators

Mahidol University
Otherlead

Study Sites (1)

Department of Ophthalmology, Siriraj Hospital Mahidol University

Bangkoknoi, Bangkok, 10700, Thailand

MeSH Terms

Conditions

Conjunctivitis, Viral

Interventions

Povidone-Iodine

Condition Hierarchy (Ancestors)

Eye Infections, ViralEye InfectionsInfectionsVirus DiseasesConjunctivitisConjunctival DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

IodophorsIodine CompoundsInorganic ChemicalsPolyvinyls

Study Officials

Adisak Trinavarat, MD
Siriraj Hospital
PRINCIPAL INVESTIGATOR

Enrollment

172 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER

Study Record Dates

First Submitted

July 18, 2010

First Posted

August 11, 2010

Study Start

July 2004

Date type not reported

This date has not been verified as actual or estimated.

NCT06282510

Nasal Antisepsis for C. Auris Prevention

Phase 4Recruiting

NCT04745663

Optimizing Preoperative Disinfection of Eyes

Phase 4Terminated

NCT05763602

PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)

Phase 4Active Not Recruiting

NCT02975921

Betadine Pleurodesis Via Tunneled Pleural Catheters

Phase 4Withdrawn

NCT01481519

A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis

Phase 3Completed

NCT00386958

A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers

Phase 2Completed

2% povidone-iodine

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

children younger than six years

women being pregnant or during lactation

history of allergy to povidone-iodine

prior ocular surgery

contact lens usage and chronic eye diseases with current eye medications.

Contact the study team to confirm eligibility.

Vinyl Compounds

Alkenes

Hydrocarbons, Acyclic

Hydrocarbons

Organic Chemicals

Povidone

Pyrrolidinones

Pyrrolidines

Heterocyclic Compounds, 1-Ring

Heterocyclic Compounds

Plastics

Polymers

Macromolecular Substances

Biomedical and Dental Materials

Manufactured Materials

Technology, Industry, and Agriculture

Primary Completion

December 2009

Actual (reported)

Study Completion

December 2009

Actual (reported)

Last Updated

August 11, 2010

Record last verified: 2010-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01179412
Data provider: ClinicalTrials.gov
Source updated: 2010-08-11
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:38:38 UTC

Locations

TH(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

2% povidone-iodine

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations